Chris Ashton

Chris Ashton has a long history of work experience in the life sciences industry. Chris began their career in 2000 as the Managing Director at Orchid BioSciences Inc. In 2002, they became the CEO of Etiologics Limited and then the CEO of Argenta Discovery in 2004. In 2010, they took the role of CEO at Pulmagen Therapeutics. In 2016, they became a Partner at SYNCONA INVESTMENT MANAGEMENT LIMITED and the CEO of Achilles Therapeutics Limited. In 2018, they became the Chairman of the Board at MacrophOx Limited. In 2019, they became an Advisor and Advisor, Life Sciences at Oxford Science Enterprises and a Non Executive Director and Chairman of the Board at PepGen. In 2020, they became a Non Executive Director at OMass Therapeutics.

Chris Ashton obtained a Bachelor of Science (B.Sc.) in Biochemistry from The University of Manchester in 1978-1981. Chris then went on to pursue a Doctor of Philosophy (Ph.D.) in Organic Chemistry at The University of Manchester from 1981-1984. After completing their Ph.D., they conducted Post-Doctoral Research at the Massachusetts Institute of Technology from 1984-1985.